Among the promising SGLT2 inhibitors, Enavogliflozin has emerged as a novel candidate for the management of T2DM (Kwak et al. 2023), with potential applications beyond diabetes management. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.